13. Fralick M, MacFadden DR. A hypothesis for why sodium glucose co-transporter 2 inhibitors have been found to cause genital infection, but not urinary tract infection. Diabetes Obes Metab. 2020;22:755–758. 14. Suzuki M, Hiramatsu M, Fuk...
SGLT2 inhibitor treatment was also associated with comparable relative risks in women and men for the safety outcomes of amputation, fracture, genital infection and urinary tract infection (all p interaction ≥ 0.17). Conclusion: SGLT2 inhibition provided comparable protection against vascular risks and...
The SGLT2 inhibitor improves pyroptosis and reduces cardiac fibrosis. Activation of AMPK by the SGLT2 inhibitor decreases the expression of downstream NLRP3, Caspase-1 and ACS. Therefore, the upregulation of the NLRP3 inflammasome complex is inhibited, which reduces the transformation of procaspase-...
Genital mycotic infections associated with SGLT2 inhibitor use are typically mild, and uncomplicated infections can be treated with oral or topical antifungals.69,70 SGLT2 inhibitors have been associated with an increased risk of euglycemic diabetic ketoacidosis (DKA).71,72 An observational study of ...
The SGLT2 inhibitor improves pyroptosis and reduces cardiac fibrosis. Activation of AMPK by the SGLT2 inhibitor decreases the expression of downstream NLRP3, Caspase-1 and ACS. Therefore, the upregulation of the NLRP3 inflammasome complex is inhibited, which reduces the transformation of procaspase-...
Genital mycotic infections with canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus: a pooled analysis of clinical studies. Curr Med Res Opin. 2014;30(6):1109–19. CAS PubMed Google Scholar Zinman B, Inzucchi SE, Lachin JM, Wanner C, ...
The most common adverse events reported was increased risk of genitourinary infection, which included genital mycotic and urinary tract infections. Most of the data from the studies comparing individuals with/without T2D came from a subgroup analysis, so it could have affected the outcomes of the ...
Moreover, the proportion of patients with genital infection and urinary tract infections, adverse events that can occur according to the mechanism of SGLT2 inhibitors, was only 2%, verifying outstanding safety of the drug. This is a signif...
However, the rate of urinary tract infection and genital infection significantly increased in patients receiving SGLT2 inhibitor such as empagliflozin or canagliflozin, particularly in women [3, 4]. Notably, the lower limb amputation significantly increased in patients receiving canagliflozin in CANVAS ...
No study has compared the cardiovascular outcomes for sodium–glucose cotransporter-2 inhibitors (SGLT2i) head-to-head against other glucose-lowering therapies, including dipeptidyl peptidase 4 inhibitor (DDP4i) or glucagon-like peptide-1 receptor agonist (GLP-1RA)—which also have cardiovascular bene...